Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “New York”

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyActive Not Recruiting
NCT02445391Phase 3Updated Jul 27, 2026
Sponsor: ECOG-ACRIN Cancer Research Group
Estrogen Receptor Negative · HER2/Neu Negative · Invasive Breast Carcinoma · Progesterone Receptor Negative
United States, South Africa
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruiting
NCT07007312Phase 3Updated Jul 27, 2026
Sponsor: Kura Oncology, Inc.
Acute Myeloid Leukemia (AML)
United States, Australia, Belgium, Canada, Czechia +11 more
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersActive Not Recruiting
NCT05538897Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma · FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma · Metastatic Endometrial Endometrioid Adenocarcinoma · Recurrent Endometrial Endometrioid Adenocarcinoma
United States
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recruiting
NCT06393374Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruiting
NCT04628767Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
United States
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeSuspended
NCT04929041Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Lung Adenocarcinoma · Lung Adenosquamous Carcinoma · Lung Non-Small Cell Carcinoma · Stage IIIB Lung Cancer AJCC v8
United States
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruiting
NCT06158841Phase 3Updated Jul 27, 2026
Sponsor: AbbVie
Multiple Myeloma
United States, Australia, Austria, Belgium, Canada +20 more
ADVENT Post Approval StudyActive Not Recruiting
NCT06431815N/AUpdated Jul 27, 2026
Sponsor: Boston Scientific Corporation
Paroxysmal Atrial Fibrillation
United States, Brazil, Canada, Chile
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)Recruiting
NCT06126276Phase 2Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Malignant Female Reproductive System Neoplasm · Malignant Solid Neoplasm · Recurrent Malignant Female Reproductive System Neoplasm · Recurrent Malignant Solid Neoplasm
United States, Puerto Rico
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruiting
NCT06096844Phase 3Updated Jul 24, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma · Stage IIIB Lung Cancer AJCC v8 · Stage IIIC Lung Cancer AJCC v8 · Stage IV Lung Cancer AJCC v8
United States
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaRecruiting
NCT05765812Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Debiopharm International SA
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype · Astrocytoma, Grade III
United States, Spain, Switzerland
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruiting
NCT07354074Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
United States, Australia, Canada, China, France +6 more
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyRecruiting
NCT05889182Phase 3Updated Jul 24, 2026
Sponsor: AbbVie
Hidradenitis Suppurativa
United States, Argentina, Australia, Austria, Belgium +32 more
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Recruiting
NCT06568939Phase 2Updated Jul 24, 2026
Sponsor: AbbVie
Non-Small Cell Lung Cancer
United States, Brazil, China, Israel, Japan +2 more
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialRecruiting
NCT04402788Phase 2, Phase 3Updated Jul 24, 2026
Sponsor: National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma
United States
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' TumorCompleted
NCT00379340Phase 3Updated Jul 24, 2026
Sponsor: Children's Oncology Group
Stage III Kidney Wilms Tumor · Stage IV Kidney Wilms Tumor
United States, Australia, Canada, Israel, New Zealand +2 more
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaRecruiting
NCT04609046Phase 1Updated Jul 24, 2026
Sponsor: National Cancer Institute (NCI)
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
United States
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityRecruiting
NCT07037433Phase 3Updated Jul 24, 2026
Sponsor: Amgen
Atherosclerotic Cardiovascular Disease · Overweight · Obesity
United States, Argentina, Australia, Austria, Belgium +31 more
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaRecruiting
NCT04166409Phase 3Updated Jul 24, 2026
Sponsor: National Cancer Institute (NCI)
Low Grade Astrocytoma · Low Grade Glioma · Metastatic Low Grade Astrocytoma · Metastatic Low Grade Glioma
United States, Canada, Puerto Rico
A Study of a Side Effects and Resource Navigation Program for People With CancerRecruiting
NCT07646847NAUpdated Jul 24, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Kidney Cancer · Bladder Cancer · Breast Cancer · Lung Cancer
United States
Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1Completed
NCT04203173NAUpdated Jul 24, 2026
Sponsor: State University of New York at Buffalo
Type 2 Diabetes
United States
Reducing Risk for Infective EndocarditisRecruiting
NCT05721781NAUpdated Jul 24, 2026
Sponsor: Wake Forest University Health Sciences
Bacteremia · Infective Endocarditis
United States
PROACTIVE-HF IDE Trial Heart Failure NYHA Class IIIActive Not Recruiting
NCT04089059NAUpdated Jul 24, 2026
Sponsor: Endotronix, Inc.
Heart Failure NYHA Class III
United States, Belgium, Ireland
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaAvailable
NCT07573215N/AUpdated Jul 24, 2026
Sponsor: Revolution Medicines, Inc.
PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Metastatic Pancreas Adenocarcinoma · Pancreatic Cancer
United States, Puerto Rico
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active Not Recruiting
NCT03155620Phase 2Updated Jul 24, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Non-Hodgkin Lymphoma · Ann Arbor Stage IV Non-Hodgkin Lymphoma · Histiocytic Sarcoma
United States, Australia, Canada, Puerto Rico

Previous page Next page